Investment Advisory Group LLC Increases Position in Eli Lilly and Company (NYSE:LLY)

Investment Advisory Group LLC raised its position in Eli Lilly and Company (NYSE:LLY) by 10.3% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 846 shares of the company’s stock after purchasing an additional 79 shares during the period. Investment Advisory Group LLC’s holdings in Eli Lilly and Company were worth $698,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the company. FPC Investment Advisory Inc. lifted its position in shares of Eli Lilly and Company by 358.3% in the fourth quarter. FPC Investment Advisory Inc. now owns 55 shares of the company’s stock valued at $45,000 after acquiring an additional 43 shares in the last quarter. Mascagni Wealth Management Inc. purchased a new stake in Eli Lilly and Company during the 4th quarter worth about $43,000. Prudent Man Investment Management Inc. acquired a new position in Eli Lilly and Company in the 4th quarter valued at about $48,000. Compass Financial Services Inc acquired a new position in Eli Lilly and Company in the 4th quarter valued at about $50,000. Finally, Capital A Wealth Management LLC purchased a new position in Eli Lilly and Company in the 4th quarter valued at about $63,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of recent research reports. HSBC downgraded shares of Eli Lilly and Company from a “buy” rating to a “reduce” rating and lowered their price target for the stock from $1,150.00 to $700.00 in a report on Monday, April 28th. Guggenheim reaffirmed a “buy” rating on shares of Eli Lilly and Company in a research note on Friday, May 23rd. Erste Group Bank lowered Eli Lilly and Company from a “buy” rating to a “hold” rating in a research note on Thursday. Cantor Fitzgerald assumed coverage on Eli Lilly and Company in a research report on Tuesday, April 22nd. They issued an “overweight” rating and a $975.00 price objective for the company. Finally, UBS Group dropped their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating for the company in a research note on Friday, May 2nd. One analyst has rated the stock with a sell rating, three have given a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and an average price target of $1,011.37.

Insider Activity at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now directly owns 5,840 shares in the company, valued at $4,778,521.60. This trade represents a 14.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $770.00 on Monday. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The company has a market capitalization of $729.76 billion, a price-to-earnings ratio of 65.76, a PEG ratio of 1.40 and a beta of 0.40. The business has a 50-day moving average of $770.87 and a 200-day moving average of $800.63.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The company had revenue of $12.73 billion during the quarter, compared to analysts’ expectations of $12.77 billion. During the same quarter in the prior year, the company earned $2.58 EPS. The firm’s revenue was up 45.2% compared to the same quarter last year. On average, equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be paid a $1.50 dividend. The ex-dividend date is Friday, May 16th. This represents a $6.00 annualized dividend and a dividend yield of 0.78%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 48.82%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.